Fernand Labrie
Publications
Page 4 of 8, showing 50 records out of 362 total, starting on record 151, ending on 200
| Publication | Category | Year |
|---|---|---|
| 212. Labrie, F. (1984) Résultats exceptionnels d'un nouveau traitement du cancer de la prostate. Interface, 5: 23-25. | Prostate Cancer | 1984 |
| 211. Labrie, F. (1985) Dreijahrige erfahrungen mit der Kombinations-therapie von Flutamid und einem LHRH-agonisten leuprolide beim Prostatakarzinom. Der Urologe. Ausg. B., B6: 342-343. | Prostate Cancer | 1985 |
| 210. Labrie, F. (1985) LHRH et ses agonistes: applications thérapeutiques. Médecine/Sciences, 1: 300-305. | Prostate Cancer | 1985 |
| 209. Labrie, F. (1987) Tratamiento del cancer de prostata mediante bloqueo hormonal completo, in: Carcinoma de Prostata: Avances en el Tratamiento Hormonal Patrocinado por la Asociacion Espanola de Urologia Barcelona, pp 61-67. | Prostate Cancer | 1987 |
| 208. Labrie, F. (1989) Criteria of response of stage D2 prostate cancer [Letter to the Editor: Reply to Newling et al. re 24: 1869-78, 1988]. Eur. J. Cancer Clin. Oncol., 25: 1259-1260. | Prostate Cancer | 1989 |
| 207. Labrie, F. (1989) Medical treatment of prostate cancer. Drug Therapy, 19: 22-37. | Prostate Cancer | 1989 |
| 206. Labrie, F. (1990) Goserelin study criticized. Oncology Times, 10: 18-19. | Prostate Cancer | 1990 |
| 205. Labrie, F. (1990) Peripheral tissues are important sites of sex steroid formation in the human: a new area of endocrinology which extends from gene structure to the first therapy that prolongs life in prostate cancer. Physiol, 21: 66-69. | Prostate Cancer | 1990 |
| 204. Labrie, F. (1991) Endocrine therapy for prostate cancer, in: Strauss, J.F., ed. Endocrinology and Metabolism Clinics of North America, Philadelphia, W.B. Saunders, pp 845-872. | Prostate Cancer | 1991 |
| 203. Labrie, F. (1991) Intracrinology. Mol. Cell. Endocrinol., 78: C113-C118. | Prostate Cancer | 1991 |
| 202. Labrie, F. (1992) Stratégie efficace et peu coûteuse pour la détection du cancer de la prostate à un stade précoce alors que la guérison est possible. Médecine/Sciences, 8: 703-706. | Prostate Cancer | 1992 |
| 201. Labrie, F. (1993) GNRH agonists in prostate cancer, in GnRH analogues - The State of the Art 1993, New York, Parthenon Publishing, pp 103-121. | Prostate Cancer | 1993 |
| 200. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. | Prostate Cancer | 1993 |
| 199. Labrie, F. (1993) Mechanism of action and pure antiandrogenic properties of Flutamide. Cancer, 72: 3816-3827. | Prostate Cancer | 1993 |
| 198. Labrie, F. (1993) Non-steroidal antiandrogens, in: Droz, J.P., Cvitkovic, E., Armand, J.P. et Khoury, S., eds: Handook of Chemotherapy in Clinical Oncology, London, Scientific Communication International Ltd., pp 389-391. | Prostate Cancer | 1993 |
| 197. Labrie, F. (1993) Present status of endocrine therapy of prostate cancer. Eur. Urol. Today, 3: 10-11. | Prostate Cancer | 1993 |
| 196. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. | Prostate Cancer | 1994 |
| 195. Labrie, F. (1994) Les antiandrogènes dans le cancer de la prostate. La Lettre du Pharmacologue, 8: 190-195. | Prostate Cancer | 1994 |
| 194. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to 342: 901-5, 1993]. Lancet, 343: 491. | Prostate Cancer | 1994 |
| 193. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to Cheney re 343: 491-2, 1994]. Lancet, 343: 976-977. | Prostate Cancer | 1994 |
| 192. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab., 80: 1066-1071. | Prostate Cancer | 1995 |
| 191. Labrie, F. (1997) Flutamide plus castration in patients with previously untreated prostate cancer [Letter to the Editor re: Noldus et al. 47: 713-8, 1996]. Urology, 50: 479. | Prostate Cancer | 1997 |
| 190. Labrie, F. (1998) Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer, 5: 341-351. | Prostate Cancer | 1998 |
| 189. Labrie, F. (1998) Optimizing combined androgen blockade in prostate cancer, in: Belldegrun, A., Kirby, R.S. et Oliver, R.T.D., eds: New Perspectives in Prostate Cancer, England, ISIS Medical Media, pp 293-311. | Prostate Cancer | 1998 |
| 188. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. | Prostate Cancer | 1999 |
| 187. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. | Prostate Cancer | 1999 |
| 186. Labrie, F. (2008) Preface. Best Pract Res Clin Endocrinol Metab, 22: pp. vii-ix. | Prostate Cancer | 2008 |
| 185. Labrie, F., Auclair, C., Cusan, L., Kelly, P.A., Pelletier, G., Ferland, L. (1978) Inhibitory effect of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat, in: Hansson, V., ed. 5th Ann. Workshop on the Testis: Endocrine Approach to Male Contraception, Hvidoure, Denmark, Int. J. of Andrology. Scriptor Publisher APS, pp 303-318. | Prostate Cancer | 1978 |
| 184. Labrie, F., Auclair, C., Cusan, L., Lemay, A., Pelletier, G., Kelly, P.A., Bélanger, A., Séguin, C., Raynaud, J.P. (1979) Antifertility effects of LHRH and its agonists in male and female rats: possible luteolytic effects of LHRH in women, in: Talwar, G.P., ed. Recent Advances in Reproduction and Regulation of Fertility, Elsevier-North Holland, Biomedical Press, pp 57-71. | Prostate Cancer | 1979 |
| 183. Labrie, F., Bélanger, A., Carmichael, R., Séguin, C., Lefebvre, F.A., Faure, N., Dupont, A. (1983) Inhibition of the testicular steroidogenic pathway in experimental animals and men, in: D'Agata, R., Lipsett, M.B.,Polosa, P. et van der Molen, H.J., eds: Recent Advances in Male Reproduction: Molecular Basis and Clinical Implications, New York, Raven Press, pp 239-248. | Prostate Cancer | 1983 |
| 182. Labrie, F., Bélanger, A., Cusan, L., Labrie, C., Simard, J., Luu-The, V., Gomez, J.L., Diamond, P., Candas, B. (1996) History of LHRH agonist and combination therapy in prostate cancer. Endocrine-Related Cancer, 3: 243-278. | Prostate Cancer | 1996 |
| 181. Labrie, F., Bélanger, A., Cusan, L., Séguin, C., Pelletier, G., Kelly, P.A., Reeves, J.J., Lefebvre, F.A., Lemay, A., Raynaud, J.P. (1980) Antifertility effects of LHRH agonists in the male. J. Androl., 1: 209-228. | Prostate Cancer | 1980 |
| 180. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., Monfette, G. (1984) Combined treatment with an LHRH agonist and a pure antiandrogen in advanced carcinoma of prostate. Lancet, 2: 1090. | Prostate Cancer | 1984 |
| 179. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., Monfette, G. (1986) Cancers évolués de la prostate: traitement par l'association d'un agoniste de la LHRH et d'un antiandrogène pur. J. Int. Med., 66: 367-368. | Prostate Cancer | 1986 |
| 178. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. | Prostate Cancer | 1993 |
| 177. Labrie, F., Bélanger, A., Dupont, A., Pelletier, G., Luu-The, V., Simard, J., Cusan, L., Labrie, C., Lachance, Y., Poulin, R., Dupont, E., Zhao, H.F., Martel, C. (1990) Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate. Médecine/Sciences, 6: 261-267. | Prostate Cancer | 1990 |
| 176. Labrie, F., Bélanger, A., Dupont, A., St-Arnaud, R. (1984) Medical castration in men: the first clinical application of LHRH agonists, in: Harrison, R.F. et Thompson, B.J., eds: Fertility and Sterility, MTP Press, pp 25-39. | Prostate Cancer | 1984 |
| 175. Labrie, F., Bélanger, A., Kelly, P.A., Séguin, C., Cusan, L., Lefebvre, F.A., Reeves, J.J., Lemay, A., Faure, N., Laroche, B., Raynaud, J.P. (1981) Antifertility effects of LHRH agonists, in: Soto, R.J., De Nicola, A.F. et Blaquier, J.A., eds: Progress in Clinical and Biological Research. Physiopathology of Diseases and Mechanisms of Hormone Action, New York, Alan R. Liss Inc., pp 273-291. | Prostate Cancer | 1981 |
| 174. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. | Prostate Cancer | 1998 |
| 173. Labrie, F., Bélanger, A., Pelletier, G., Séguin, C., Cusan, L., Kelly, P.A., Lemay, A., Auclair, C., Raynaud, J.P. (1980) LHRH agonists: inhibition of testicular functions and possible clinical applications, in: Cunningham, G.R., Schill, W.B. et Hafez, E.S.E., eds: Clinics in Andrology. Regulation of Male Fertility, The Netherlands, Martinus Nijoff Publ., B.V., The Hague, pp 65-75. | Prostate Cancer | 1980 |
| 172. Labrie, F., Bélanger, A., Séguin, C., Cusan, L., Pelletier, G., Lefebvre, F.A., Kelly, P.A., Ferland, L., Reeves, J.J., Lemay, A., Raynaud, J.P. (1981) Inhibition of testicular and ovarian functions by LHRH agonists, in: Jagiello, G. et Vogel, H.J., eds: Bioregulators of Reproduction, New York, NY, USA, Academic Press, pp 305-341. | Prostate Cancer | 1981 |
| 171. Labrie, F., Bélanger, A., Séguin, C., Pelletier, G., Kelly, P.A., Lefebvre, F.A., Massicotte, J., Borgus, J.P., Lemay, A., van der Ohe, M. (1981) Antifertility effects of LHRH agonists, in: Semm, K. et Mettler, L., eds: Proc. III World Congress on Human Reproduction, Excerta Medica, ICS 551, pp 116-125. | Prostate Cancer | 1981 |
| 170. Labrie, F., Bélanger, A., Séguin, C., Pelletier, G., Lefebvre, F.A., Massicotte, J., Kelly, P.A., Borgus, J.P. (1981) LHRH and sexual functions: inhibition at the pituitary and gonadal levels, in: Bizollon, C.A., ed. Physiological peptides and new trends in radioimmunology, Elsevier-North Holland, Biomedical Press, pp 57-70. | Prostate Cancer | 1981 |
| 169. Labrie, F., Bélanger, A., Séguin, C., Pelletier, G., Lefebvre, F.A., Reeves, J.J., Kelly, P.A., Massicotte, J., Cusan, L. (1981) LHRH and down regulation of testicular receptors and function, in: Frajese, G., ed. Oligospermia. Recent Progress in Andrology, New York, NY, USA, Raven Press, pp 337-345. | Prostate Cancer | 1981 |
| 168. Labrie, F., Bélanger, A., Simard, J., Labrie, C., Dupont, A. (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first line therapy. Cancer, 71: 1059-1067. | Prostate Cancer | 1993 |
| 167. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. | Prostate Cancer | 1995 |
| 166. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Cusan, L., Gomez, J., Diamond, P., Candas, B. (1996) Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate (Chapter 16), in: Belaisch, J., Drodowsky, M.A. et Vermeulen, A., eds: Progrès en Andrologie: Endocrinologie Masculine, Doin, pp 215-229. | Prostate Cancer | 1996 |
| 165. Labrie, F., Bélanger, A., Veilleux, R., Lacoste, D., Labrie, C., Marchetti, B., Poulin, R., Dupont, A., Cusan, L., Luthy, I. (1988) Rationale for maximal androgen withdrawal in the therapy of prostate cancer, in: Furr, M. et Denis, L., eds: Baillieres Clinics in Oncology on Prostate Cancer, London, Saunders Company, pp 597-619. | Prostate Cancer | 1988 |
| 164. Labrie, F., Candas, B., Cusan, L., Diamond, P., Gomez, J.L. (1996) Antiandrogen story erred [Letter to the Editor]. The Medical Post, 32: | Prostate Cancer | 1996 |
| 163. Labrie, F., Candas, B., Cusan, L., Gomez, J.L., Diamond, P., Lemay, M. (1997) Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen [Letter to the Editor: Reply to Brown and Feuer re 47: 212-7, 1996]. Urology, 49: 306-307. | Prostate Cancer | 1997 |